RaQUA2

September 17,2021

Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma.

fda

April 22,2020

NDA Application of XG005 will follow a 505(B)(2) regulatory pathway based on FDA’S feedback

News_04May2019

May 4, 2019

XGene Pharmaceutical Closed the B Plus

Round Financing

News_25Oct2018

October 25, 2018

XGene Pharmaceutical Closed US$20 Million B Round Financing